

## COVID-19 Vermont Vaccination Eligibility Parameters

Updated 07.25.2022; Trey Dobson

CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

<b>Pfizer-BioNTech (Comirnaty)</b>			
Age	Timing	Eligibility	Timing
6 months to 4 years <sup>1</sup>	3 dose primary series using pediatric dose (3 µg/0.2 mL)	Anyone ages 6 months to 4 years	3 doses; the first 2 doses are separated by 3 weeks followed by a third dose 8 weeks after the second dose
	Third dose using pediatric dose (3 µg/0.2 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  The third dose is considered a part of the primary series for those meeting the criteria above	28+ days after second dose
	Booster	Not eligible	Not eligible
5 years to 11 years <sup>1</sup>	Primary series using pediatric dose (10 µg/0.2 mL)	Anyone ages 5 years to 11 years	2 doses separated by 3 weeks
	Third dose using pediatric dose (10 µg/0.2 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  <i>Note:</i> • The third dose is considered a part of the primary series for those meeting the criteria above	28+ days after second dose
	1 <sup>st</sup> booster using pediatric dose (10 µg/0.2 mL)	Anyone ages 5 years to 11 years	5+ months after second dose
Ages 12 years and older <sup>1</sup>	2 dose primary series (30 µg/0.3 mL)	Anyone ages 12 years and older	2 doses separated by 3-8 weeks <sup>3</sup>
	Third dose (30 µg/0.3 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  The third dose is considered a part of the primary series for those meeting the criteria above  These individuals may also receive a booster once 5 months has elapsed	28+ days after second dose
	1 <sup>st</sup> booster using "full dose" of Pfizer (30 µg/0.3 mL)	Regardless of which COVID-19 vaccine an individual received in the primary series, individuals meeting the criteria below may receive a Pfizer booster • Anyone ages 12 years and older	For general population, 5+ months after second dose  For immunocompromised <sup>2</sup> , 3+ months after third dose
	2 <sup>nd</sup> booster using "full dose" of Pfizer (30 µg/0.3 mL)	Regardless of which COVID-19 vaccine an individual received in the primary series, individuals meeting the criteria below may receive a Pfizer booster • Anyone ages 50 years and older, OR • Those ages 12 years and older and moderately to severely immunocompromised <sup>2</sup>	4 months after 1 <sup>st</sup> booster

## COVID-19 Vermont Vaccination Eligibility Parameters

Updated 07.25.2022; Trey Dobson

CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

<b>Moderna (SPIKEVAX)</b>			
Age	Timing	Eligibility	Timing
Ages 6 months to 5 years <sup>1</sup>	2 dose primary series (25 µg/0.25 mL)	Anyone ages 6 months to 5 years	2 doses separate by 4 weeks
	Third dose (25 µg/0.25 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  The third dose is considered a part of the primary series for those meeting the criteria above	28+ days after second dose
	Booster	Not eligible	Not eligible
Ages 6 years to 11 years <sup>1</sup>	2 dose primary series (50 µg/0.5 mL)	Anyone ages 6 years to 11 years	2 doses separate by 4 weeks
	Third dose (50 µg/0.5 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  The third dose is considered a part of the primary series for those meeting the criteria above	28+ days after second dose
	Booster	Not eligible	Not eligible
Ages 12 years to 17 years <sup>1</sup>	2 dose Primary series (100 µg/0.5 mL)	Anyone ages 12 years to 17 years	2 doses separate by 4 weeks
	Third dose (100 µg/0.5 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  The third dose is considered a part of the primary series for those meeting the criteria above	28+ days after second dose
	Booster	Not eligible	Not eligible
Ages 18 years and older <sup>1</sup>	2 dose primary series (100 µg/0.5 mL)	Anyone ages 18 years and older	2 doses separated by 4-8 weeks <sup>3</sup>
	Third dose (100 µg/0.5 mL)	Must be moderately to severely immunocompromised <sup>2</sup>  The third dose is considered a part of the primary series for those meeting the criteria above  These individuals may also receive a booster once 5 months has elapsed	28+ days after second dose
	1 <sup>st</sup> booster using "half dose" (50 µg/0.25 mL)	Regardless of which COVID-19 vaccine an individual received in the primary series, those meeting the criteria below may receive a half dose Moderna booster <ul style="list-style-type: none"> <li>• Anyone ages 18 and older</li> </ul>	For general population, 5+ months after second dose  For immunocompromised <sup>2</sup> , 3+ months after third dose

## COVID-19 Vermont Vaccination Eligibility Parameters

Updated 07.25.2022; Trey Dobson

CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

	2 <sup>nd</sup> booster using “half dose” (50 µg/0.25 mL)	Regardless of which COVID-19 vaccine an individual received in the primary series, individuals meeting the criteria below may receive a half dose Moderna booster <ul style="list-style-type: none"> <li>• Anyone ages 50 and older OR</li> <li>• Ages 18 and older and moderately to severely immunocompromised<sup>2</sup></li> </ul>	4 months after 1 <sup>st</sup> booster
--	---	---	--

<b>Novavax (Nuvaxovid)</b>			
<b>Age</b>	<b>Timing</b>	<b>Eligibility</b>	<b>Timing</b>
Ages 18 and older	2 dose primary series (5 µg/50 µg/0.5 mL)	Anyone ages 18 years and older	2 doses separated by 3-8 weeks
	Third dose Booster	Not eligible; a 3rd primary dose of Novavax COVID-19 vaccine is not currently authorized	
	Booster	Not eligible; a booster of Novavax COVID-19 vaccine is not currently authorized	

## COVID-19 Vermont Vaccination Eligibility Parameters

Updated 07.25.2022; Trey Dobson

CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

Pfizer and Moderna vaccines are **preferred** over Johnson & Johnson COVID-19 vaccine.

Administer Johnson & Johnson COVID-19 vaccine only in the following situations:

- When there is a contraindication to Pfizer and Moderna COVID-19 vaccines
- When a person wishes to receive the Johnson & Johnson vaccine despite concerns of safety and effectiveness

<b>Janssen (not licensed, remains as EUA)</b>			
Age	Timing	Eligibility	Timing
Ages 18 and older	1 dose primary series (5×10 <sup>10</sup> vp/ 0.5 mL)	Anyone age 18 and older	1 dose
	Additional dose using Pfizer or Moderna	Must be both <ul style="list-style-type: none"> <li>• Ages 18 and older AND</li> <li>• Moderately to severely immunocompromised<sup>2</sup></li> </ul> Use Pfizer or Moderna, not an additional dose of Johnson & Johnson	28+ days after first dose
	1 <sup>st</sup> booster using “full dose” (5×10 <sup>10</sup> vp/ 0.5 mL)	Regardless of which COVID-19 vaccine an individual received in the primary series, those meeting the criteria below may receive a Johnson & Johnson booster <ul style="list-style-type: none"> <li>• Anyone ages 18 and older</li> </ul>	2+ months after additional dose
	2 <sup>nd</sup> booster using Pfizer or Moderna	Anyone ages 18 and older  <i>Note:</i> <ul style="list-style-type: none"> <li>• For those who received Johnson &amp; Johnson for primary series and 1<sup>st</sup> booster, a 2<sup>nd</sup> booster may be given using Pfizer or Moderna, not an additional dose of Johnson &amp; Johnson</li> </ul>	4+ months after 1 <sup>st</sup> booster

## COVID-19 Vermont Vaccination Eligibility Parameters

Updated 07.25.2022; Trey Dobson

CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States  
<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

- <sup>1</sup> Individuals who will advance into the next age group of eligibility between any doses in the primary series may elect to receive the concentration for the older age group as their initial dose and/or for subsequent doses.

For example, a child 4 years of age presents for the 1<sup>st</sup> dose of Pfizer vaccine. She will turn 5 years of age prior to completing the primary series. The individual may choose to

- Use the dose concentration for ages 5 years to 11 years for the initial and subsequent doses in the primary series, OR
- Use the dose concentration for ages 6 months to 4 years for the initial dose and use the dose concentration for ages 5 years to 11 years for the subsequent doses in the primary series, OR
- Use the dose concentration for ages 6 months to 4 years for the initial and subsequent doses in the primary series.

- <sup>2</sup> Definition of moderately to severely immunocompromised

<b>CDC list of moderately to severely immunocompromised conditions</b>
<ul style="list-style-type: none"><li>• Been receiving active cancer treatment for tumors or cancers of the blood</li><li>• Received an organ transplant and are taking medicine to suppress the immune system</li><li>• Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system</li><li>• Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)</li><li>• Advanced or untreated HIV infection</li><li>• Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response</li></ul> <p><a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html</a></p>

- <sup>3</sup> Notes:

- All people ages 12 years and older should receive an age-appropriate booster dose and formulation of COVID-19 vaccine, even if they were age 11 years or younger at the time of the primary series
- An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years
- A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for:
  - People who are moderately to severely immunocompromised
  - Adults ages 65 years and older
  - Others who need rapid protection due to increased concern about community transmission or risk of severe disease

<b>People who received passive antibody products</b>
<ul style="list-style-type: none"><li>• Passive antibody product used for post-exposure prophylaxis or COVID-19 treatment:<ul style="list-style-type: none"><li>○ No deferral period, may administer vaccine at anytime after receiving antibodies</li><li>○ Getting vaccine is priority</li></ul></li><li>• <i>After</i> vaccination, tixagevimab/cilgavimab (EVUSHELD™) should be deferred for at least two weeks</li></ul> <p><a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination</a></p>